South African health officials are urging COVID-19 vaccine manufacturer Aspen to keep its plant in the Eastern Cape province open. This follows a Reuters article quoting Aspen’s senior director saying they may have to shut down as there have been no orders for their rebranded COVID vaccine. A South African-owned subsidiary of pharmaceutical giant Aspen struck a deal with American company Johnson & Johnson in March to package, price, sell and distribute its vaccine in Africa. This vaccine was rebranded as Aspenovax. The move was hailed by many as there had been much concern about Africa’s reliance on imported vaccines which were often costly and at times in short supply. But there have been no orders for Aspenovax. South Africa’s National Health Department Spokesperson Foster Mohale said the lack of orders is due to low vaccination rates not only at home, but globally. “Vaccine hesitancy is one of the factors …